{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:29:24Z","timestamp":1772753364072,"version":"3.50.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":2128,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,4]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The primary objective of this study was to evaluate the safety and clinical efficacy of autologous cytokine-induced killer (CIK) cells combined with cyclophosphamide in the treatment of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome patients. We evaluated five POEMS syndrome patients treated with autologous CIK cell immunotherapy combined with cyclophosphamide from 1 May 2012 to 30 November 2014. The Overall Neuropathy Limitation Scale (ONLS), computed tomography of the chest and abdomen, ultrasound of the abdomen, serum vascular endothelial growth factor (VEGF) level and lymphocyte count findings in the five patients were recorded. The median age of the patients was 40 years (range: 25\u201362), and all the patients were male. CIK cells were generated routinely from peripheral blood mononuclear cells (PBMCs) of all five patients, and the numbers of CIK cells increased by approximately 105-fold after 14 days of culture. All five patients (100%) responded to their neuropathy treatment, the ONLS scores were reduced by at least 1 and a paired-sample t-test revealed a significant difference (t = 5\u00b7715, P = 0\u00b7003 &amp;lt; 0\u00b701). The extravascular volume overload responses indicated partial remission (PR = 60%) or stable disease (SD = 40%), and no cases of progressive disease (PD) or complete remission (CR) were observed. During clinical treatment, the serum VEGF of patient 5 decreased after one cycle of transfusion within 1 month. The lymphocyte counts of all the patients increased significantly after CIK transfusion, and a paired-sample t-test revealed a significant difference (t = 5\u00b7101, P = 0\u00b7004 &amp;lt; 0\u00b701). Autologous CIK cell infusion combined with cyclophosphamide was found to be highly safe and elicited no adverse reactions. CIK cells can improve both the symptoms and quality of life, decrease serum VEGF levels and increase lymphocyte counts in patients with POEMS syndrome.<\/jats:p>","DOI":"10.1111\/cei.12755","type":"journal-article","created":{"date-parts":[[2015,12,13]],"date-time":"2015-12-13T07:28:43Z","timestamp":1449991723000},"page":"83-89","source":"Crossref","is-referenced-by-count":5,"title":["Autologous cytokine-induced killer (CIK) cell immunotherapy combined with cyclophosphamide in five patients with POEMS syndrome"],"prefix":"10.1093","volume":"184","author":[{"given":"L","family":"Ma","sequence":"first","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Institute of Basic Medicine, School of Life Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Bo","sequence":"additional","affiliation":[{"name":"Department of Haematology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Immunology, Institute of Basic Medicine, School of Life Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chinese PLA General Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,1,19]]},"reference":[{"key":"2021111804092497200_cei12755-bib-0001","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/ajh.23644","article-title":"POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Dispenzieri","year":"2014","journal-title":"Am J Hematol"},{"key":"2021111804092497200_cei12755-bib-0002","first-page":"CD006828","article-title":"Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome","volume":"6","author":"Kuwabara","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2021111804092497200_cei12755-bib-0003","first-page":"CD006828","article-title":"Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome","author":"Kuwabara","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"2021111804092497200_cei12755-bib-0004","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1182\/blood-2012-03-378992","article-title":"How I treat POEMS syndrome","volume":"119","author":"Dispenzieri","year":"2012","journal-title":"Blood"},{"key":"2021111804092497200_cei12755-bib-0005","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1182\/blood-2010-12-328112","article-title":"Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome","volume":"117","author":"Li","year":"2011","journal-title":"Blood"},{"key":"2021111804092497200_cei12755-bib-0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clml.2013.12.009","article-title":"Autologous stem cell transplantation for POEMS syndrome","volume":"14","author":"Nakaseko","year":"2014","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"2021111804092497200_cei12755-bib-0007","doi-asserted-by":"crossref","first-page":"363","DOI":"10.7150\/jca.2.363","article-title":"Cytokine induced killer cells as promising immunotherapy for solid tumors","volume":"2","author":"Sangiolo","year":"2011","journal-title":"J Cancer"},{"key":"2021111804092497200_cei12755-bib-0008","doi-asserted-by":"crossref","first-page":"195691","DOI":"10.1155\/2013\/195691","article-title":"Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy","volume":"2013","author":"Zhang","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2021111804092497200_cei12755-bib-0009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-010-0887-7","article-title":"Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)","volume":"137","author":"Hontscha","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021111804092497200_cei12755-bib-0010","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1158\/1078-0432.CCR-11-2442","article-title":"Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma","volume":"18","author":"Liu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021111804092497200_cei12755-bib-0011","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/bjc.2013.90","article-title":"Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma","volume":"108","author":"Yoshimura","year":"2013","journal-title":"Br J Cancer"},{"key":"2021111804092497200_cei12755-bib-0012","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s00262-012-1289-2","article-title":"Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer","volume":"61","author":"Shi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"2021111804092497200_cei12755-bib-0013","doi-asserted-by":"crossref","first-page":"473245","DOI":"10.1155\/2012\/473245","article-title":"Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma","volume":"2012","author":"Jakel","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2021111804092497200_cei12755-bib-0014","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/14653249.2012.681038","article-title":"Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol","volume":"14","author":"Rutella","year":"2012","journal-title":"Cytotherapy"},{"key":"2021111804092497200_cei12755-bib-0015","first-page":"595","article-title":"Lymphokine-activated killer cells: a new approach to immunotherapy of cancer","volume":"75","author":"Rosenberg","year":"1985","journal-title":"J Natl Cancer Inst"},{"key":"2021111804092497200_cei12755-bib-0016","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1479-5876-11-83","article-title":"Cytokine-induced killer cells promote antitumor immunity","volume":"11","author":"Jiang","year":"2013","journal-title":"J Transl Med"},{"key":"2021111804092497200_cei12755-bib-0017","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/sj.bjc.6690800","article-title":"Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma","volume":"81","author":"Schmidt-Wolf","year":"1999","journal-title":"Br J Cancer"},{"key":"2021111804092497200_cei12755-bib-0018","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbmt.2004.11.019","article-title":"A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma","volume":"11","author":"Leemhuis","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021111804092497200_cei12755-bib-0019","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"key":"2021111804092497200_cei12755-bib-0020","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2011.05.012","article-title":"Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"17","author":"Laport","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021111804092497200_cei12755-bib-0021","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-014-1618-7","article-title":"Homing of cytokine-induced killer cells during the treatment of acute promyelocytic leukemia","volume":"100","author":"Wang","year":"2014","journal-title":"Int J Hematol"},{"key":"2021111804092497200_cei12755-bib-0022","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4049\/jimmunol.153.4.1687","article-title":"A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency","volume":"153","author":"Lu","year":"1994","journal-title":"J Immunol"},{"key":"2021111804092497200_cei12755-bib-0023","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/cimm.1996.0094","article-title":"Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells","volume":"169","author":"Schmidt-Wolf","year":"1996","journal-title":"Cell Immunol"},{"key":"2021111804092497200_cei12755-bib-0024","doi-asserted-by":"crossref","first-page":"621414","DOI":"10.1155\/2011\/621414","article-title":"Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells","volume":"2011","author":"Wang","year":"2011","journal-title":"Clin Dev Immunol"},{"key":"2021111804092497200_cei12755-bib-0025","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/jnnp.2005.081547","article-title":"A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale","volume":"77","author":"Graham","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2021111804092497200_cei12755-bib-0026","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/1097-4598(200007)23:7<1051::AID-MUS7>3.0.CO;2-V","article-title":"Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome","volume":"23","author":"Hashiguchi","year":"2000","journal-title":"Muscle Nerve"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.12755","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/184\/1\/83\/41126391\/cei12755.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/184\/1\/83\/41126391\/cei12755.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T01:08:44Z","timestamp":1718240924000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/184\/1\/83\/6412146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,19]]},"published-print":{"date-parts":[[2016,3,4]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.12755","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2016,4]]},"published":{"date-parts":[[2016,1,19]]}}}